Insulin therapy for type 2 diabetes.
Open accessThe DOI matches its Crossref record; 64 of the 66 references it cites were found in a registry or an index.
Abstract
A number of landmark randomized clinical trials established that insulin therapy reduces microvascular complications (1,2). In addition, recent follow-up data from the U.K. Prospective Diabetes Study (UKPDS) suggest that early insulin treatment also lowers macrovascular risk in type 2 diabetes (3). Whereas there is consensus on the need for insulin, controversy exists on how to initiate and intensify insulin therapy. The options for the practical implementation of insulin therapy are many. In this presentation, we will give an overview of the evidence on the various insulin regimens commonly used to treat type 2 diabetes. Secondary analyses of the aforementioned landmark trials endeavored to establish a glycemic threshold value below which no complications would occur. The UKPDS found no evidence for such a threshold for A1C, but instead showed that better glycemic control was associated with reduced risks of complications over the whole glycemic range (“the lower the better”) (4). For the management of type 2 diabetes, this resulted in the recommendation to “maintain glycemic levels as close to the nondiabetic range as possible” (5). However, in contrast to the UKPDS, the Kumamoto study observed a threshold, with no exacerbation of microvascular complications in patients with type 2 diabetes whose A1C was <6.5%, suggesting no additional benefit in lowering A1C below this level (2). Moreover, the intensive glycemia treatment arm of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, targeting A1C <6.0%, was discontinued because of higher mortality in this group compared with the standard therapy group targeting A1C from 7.0 to 7.9% (6). Therefore, the American Diabetes Association (ADA) recommendation of an A1C target <7.0% seems the most balanced compromise at present (7). Another important conclusion of the UKPDS was that the risk reductions in long-term complications were related to the levels of glycemic control …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Relationships between mean end point daily insulin dose (A) and the frequency of patient contact (clinical visits and telephone contacts combined) (B) and mean reduction in A1C, and between mean end point daily insulin dose and mean weight gain (C), during nine randomized trials investigating insulin initiation with NPH insulin, insulin detemir, or insulin glargine. Included studies are Bretzel et al. (34), Fritsche et al. (35), Hermansen et al. (28), Holman et al. (32), Philis-Tsimikas et al. (33), Riddle et al. (27), Rosenstock et al. (29), Yki-Järvinen et al. (36), and Yki-Järvinen et al. (37) (A and C). B does not include Holman, since this publication did not specify the number of interim telephone contacts. Two trials (28,35) did not report mean end point daily insulin dose as units per kilogram per day. We calculated the desired figures from the mean end point dose reported as units per day and mean body weight at study end. Three studies (Riddle and the two studies of Yki-Järvinen [27,36,37]) did not report reduction in A1C. We calculated these values from mean baseline and end point A1C levels.](https://figures.cochat.ai/paper-figures/1e9a45de404c4ea4814181c7adb4b0e3/insulin-therapy-for-type-2-diabetes-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although increasing the basal insulin dose often improves glycemic control, it can also be associated with increased risk of hypoglycemia and weight gain, resulting in inadequate intensification of insulin dose in clinical practice.1”
From Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (2022) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479 · cited 3×
“Included studies are Bretzel et al. (34), Fritsche et al. (35), Hermansen et al. (28), Holman et al. (32), Philis-Tsimikas et al. (33), Riddle et al. (27), Rosenstock et al. (29), Yki-Järvinen et al. (36), and Yki-Järvinen et al. (37) (A and C).”
Gerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818 · cited 1×
“Nevertheless, both longacting insulin analogs (detemir and glargine) have a limited peak effect and a longer mean duration of action compared with NPH insulin (with glargine having a slightly longer action than detemir [13,16,17]).”
Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794
Weng, J., Li, Y., Xu, W., Shi, L., Zhang, Q., Zhu, D., Hu, Y., Zhou, Z., Yan, X., Tian, H., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60762-x · Cited by 780
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa075392 · Cited by 710
Hirsch, I. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040832 · Cited by 667
Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Yki-Järvinen, H., Dressler, A., Ziemen, M., & HOE 901/300s Study Group (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1130 · Cited by 579 · cited 1×
“[27, 36,37]) did not report reduction in HbA1c.”
Initiating Insulin Therapy in Type 2 Diabetes
Raskin, P., Allen, E., Hollander, P., Lewin, A., Gabbay, R. A., Hu, P., Bode, B., Garber, A., & for the INITIATE Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.2.260 · Cited by 560
Psychological Insulin Resistance in Patients With Type 2 Diabetes
Polonsky, W. H., Fisher, L., Guzman, S., Villa-Caballero, L., & Edelman, S. V. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2543 · Cited by 551
Donnelly, L. A., Morris, A. D., Frier, B. M., Ellis, J. D., Donnan, P. T., Durrant, R., Band, M. M., Reekie, G., & Leese, G. P. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01501.x · Cited by 511
Rosenstock, J., Davies, M., Home, P. D., Larsen, J., Koenen, C., & Schernthaner, G. (2008) · Diabetologia · doi:10.1007/s00125-007-0911-x · Cited by 447
Hypoglycemia in Type 2 Diabetes
Zammitt, N. N., & Frier, B. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2948 · Cited by 435
Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study
Yki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Tulokas, T., Hulme, S., Hardy, K., McNulty, S., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0132-0 · Cited by 434 · cited 3×
“Included studies are Bretzel et al. (34), Fritsche et al. (35), Hermansen et al. (28), Holman et al. (32), Philis-Tsimikas et al. (33), Riddle et al. (27), Rosenstock et al. (29), Yki-Järvinen et al. (36), and Yki-Järvinen et al. (37) (A and C).”
Yki-Järvinen, H., Ryysy, L., Nikkilä, K., Tulokas, T., Vanamo, R., & Heikkilä, M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-5-199903020-00002 · Cited by 433
The Burden of Treatment Failure in Type 2 Diabetes
Brown, J. B., Nichols, G. A., & Perry, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.7.1535 · Cited by 424
Horvath, K., Jeitler, K., Berghold, A., Ebrahim, S. H., Gratzer, T. W., Plank, J., Kaiser, T., Pieber, T. R., & Siebenhofer, A. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005613.pub3 · Cited by 366
Initial management of glycemia in type 2 diabetes mellitus
Nathan, D. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp021106 · Cited by 359
Abraira, C., Colwell, J. A., Nuttall, F. Q., Sawin, C. T., Nagel, N. J., Comstock, J. P., Emanuele, N. V., Levin, S. R., Henderson, W., Lee, H. S., et al. (1995) · Diabetes Care · doi:10.2337/diacare.18.8.1113 · Cited by 355
Fritsche, A., Schweitzer, M. A., Hring, H.-U., & and the 4001 Study Group* (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-12-200306170-00006 · Cited by 331
Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus
Yki-Järvinen, H., Kauppila, M., Kujansuu, E., Lahti, J., Marjanen, T., Niskanen, L., Rajala, S., Ryysy, L., Salo, S., Seppälä, P., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211123272005 · Cited by 324
Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes
Davies, M., Storms, F., Shutler, S., Bianchi-Biscay, M., Gomis, R., & for the AT.LANTUS Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1282 · Cited by 314
Bretzel, R. G., Nuber, U., Landgraf, W., Owens, D. R., Bradley, C., & Linn, T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60485-7 · Cited by 305
Combination therapies with insulin in type 2 diabetes
Yki-Järvinen, H. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.758 · Cited by 300
Hypoglycaemia in insulin‐treated Type 2 diabetes: frequency, symptoms and impaired awareness
Henderson, J. N., Allen, K. V., Deary, I. J., & Frier, B. M. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.01072.x · Cited by 287
Philis-Tsimikas, A., Charpentier, G., Clauson, P., Ravn, G. M., Roberts, V. L., & Thorsteinsson, B. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.10.020 · Cited by 278
Plank, J., Bodenlenz, M., Sinner, F., Magnes, C., Görzer, E., Regittnig, W., Endahl, L. A., Draeger, E., Zdravkovic, M., & Pieber, T. R. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1107 · Cited by 271 · cited 1×
“Nevertheless, both longacting insulin analogs (detemir and glargine) have a limited peak effect and a longer mean duration of action compared with NPH insulin (with glargine having a slightly longer action than detemir [13,16,17]).”
Herman, W. H., Ilag, L. L., Johnson, S. L., Martin, C. L., Sinding, J., Al Harthi, A., Plunkett, C. D., LaPorte, F. B., Burke, R., Brown, M. B., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1568 · Cited by 265
Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus
Siebenhofer, A., Plank, J., Berghold, A., Jeitler, K., Horvath, K., Narath, M., Gfrerer, R., & Pieber, T. R. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003287.pub4 · Cited by 264
Frequency and Morbidity of Severe Hypoglycaemia in Insulin‐treated Diabetic Patients
MacLeod, K. M., Hepburn, D. A., & Frier, B. M. (1993) · Diabetic Medicine · doi:10.1111/j.1464-5491.1993.tb00051.x · Cited by 251
Raskin, P., Bode, B. W., Marks, J. B., Hirsch, I. B., Weinstein, R. L., McGill, J. B., Peterson, G. E., Mudaliar, S. R., & Reinhardt, R. R. (2003) · Diabetes Care · doi:10.2337/diacare.26.9.2598 · Cited by 249
Heise, T., & Pieber, T. R. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00756.x · Cited by 239
Porcellati, F., Rossetti, P., Busciantella, N. R., Marzotti, S., Lucidi, P., Luzio, S., Owens, D. R., Bolli, G. B., & Fanelli, C. G. (2007) · Diabetes Care · doi:10.2337/dc07-0002 · Cited by 219
Advancing Insulin Therapy in Type 2 Diabetes Previously Treated With Glargine Plus Oral Agents
Rosenstock, J., Ahmann, A. J., Colon, G., Scism-Bacon, J., Jiang, H., & Martin, S. (2008) · Diabetes Care · doi:10.2337/dc07-1122 · Cited by 191
Malone, J. K., Kerr, L. F., Campaigne, B. N., Sachson, R. A., & Holcombe, J. H. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.12.015 · Cited by 167
Cryer, P. E. (2006) · Diabetologia · doi:10.1007/s00125-006-0448-4 · Cited by 161
Nakar, S., Yitzhaki, G., Rosenberg, R., & Vinker, S. (2007) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2006.02.004 · Cited by 159
Mullins, P. R., Sharplin, P., Yki‐Järvinen, H., Riddle, M. C., & Häring, H. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.08.020 · Cited by 156
Liebl, A., Prager, R., Binz, K., Kaiser, M., Bergenstal, R., Gallwitz, B., & PREFER Study Group (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00915.x · Cited by 149
Scholtz, H. E., Pretorius, S. G., Wessels, D. H., & Becker, R. H. A. (2005) · Diabetologia · doi:10.1007/s00125-005-1916-y · Cited by 126
Spyer, G., Hattersley, A. T., MacDonald, I., Amiel, S., & MacLeod, K. M. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03322-5 · Cited by 126
Refining basal insulin therapy: what have we learned in the age of analogues?
DeVries, J. H., Nattrass, M., & Pieber, T. R. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.762 · Cited by 94
Self-citationNice insulins, pity about the evidence
Holleman, F., & Gale, E. A. M. (2007) · Diabetologia · doi:10.1007/s00125-007-0763-4 · Cited by 78
Houlden, R. L., Ross, S. A., Harris, S. B., Yale, J., Sauriol, L., & Gerstein, H. C. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.03.021 · Cited by 62
Yki-Järvinen, H., Esko, N., Helve, E., & Taskinen, M. (1988) · The American Journal of Medicine · doi:10.1016/0002-9343(88)90412-3 · Cited by 49
Standl, E., Maxeiner, S., & Raptis, S. (2006) · Hormone and Metabolic Research · doi:10.1055/s-2006-925222 · Cited by 47
Treatment of Type 2 Diabetes With Combined Therapy
Massi‐Benedetti, M., & Orsini-Federici, M. (2008) · Diabetes Care · doi:10.2337/dc08-s233 · Cited by 44
Sélam, J.-L., Koenen, C., Weng, W., & Meneghini, L. (2008) · Current Medical Research and Opinion · doi:10.1185/030079907x242755 · Cited by 44
Combined Therapy With Insulin Plus Oral Agents: Is There Any Advantage?
Riddle, M. C. (2008) · Diabetes Care · doi:10.2337/dc08-s231 · Cited by 41
Ryan, M., Livingstone, M. B. E., Ducluzeau, P.-H., Sallé, A., Genaitay, M., & Ritz, P. (2008) · Diabetes Care · doi:10.2337/dc07-1171 · Cited by 29
Cryer, P. E. (2006) · Diabetes Care · doi:10.2337/dc-06-1670 · Cited by 15
Swinnen, S. G. H. A., & DeVries, J. H. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.02.009 · Cited by 14
Self-citationDeVries, J. H. (2006) · Diabetologia · doi:10.1007/s00125-006-0166-y · Cited by 12
Self-citationManagement of Type 2 Diabetes — Polling Results
Halperin, F., Ingelfinger, J. R., & McMahon, G. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmclde0801078 · Cited by 11
Cited by
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597
“Although increasing the basal insulin dose often improves glycemic control, it can also be associatedwith increased risk of hypoglycemia andweight gain, resulting in inadequate intensification of insulin dose in clinical practice.(1) When added to basal insulin, selective glucagon-like peptide-1 (GLP-1) receptor agoni…”
BackgroundSemaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.
Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00070 · Cited by 412
Nicholls, S. J., Bhatt, D. L., Buse, J. B., Prato, S. D., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Nauck, M. A., Nissen, S. E., Sattar, N., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2023.09.007 · Cited by 248
Type 2 Diabetes: The Pathologic Basis of Reversible β-Cell Dysfunction
White, M. G., Shaw, J. A. M., & Taylor, R. (2016) · Diabetes Care · doi:10.2337/dc16-0619 · Cited by 174
Metadata
- Authors
- Swinnen, S. G., Hoekstra, J. B., & DeVries, J. H.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Corresponding author
- Swinnen, Sanne G.
- ORCID
- DeVries, J. Hans
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-11-01
- Volume
- 32
- Issue
- suppl_2
- Pages
- S253-S259
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2811456
- OpenAlex
- W2131037080
- Semantic Scholar
- a5b8f30bf6ffc652e3e70e51ae28659874032190
- Cited by
- 181
- References
- 66
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 15 · 2023: 21 · 2022: 19 · 2021: 12 · 2020: 14 · 2019: 7 · 2018: 8 · 2017: 10 · 2016: 11 · 2015: 7 · 2014: 11 · 2013: 10 · 2012: 10
- FWCI
- 0.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Sanofi
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin therapy, type 2 diabetes, insulin regimens, glycemic control, HbA1c targets, microvascular complications, UKPDS, ACCORD trial, tight glycemic control
- MeSH terms
- Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemia, Hypoglycemic Agents, Insulin, Quality of Life, Patient Satisfaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.